Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Clinical Contact
G1 Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
82 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Henan Cancer Hospital
Zijingshan, Henan, China
- Wuhan Union Hospital
Wuhan, Hubei, China
- Jilin Provincial Tumor Hospital
Changchun, Jilin, China
- the First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
- the Affiliated Tumor Hospital of Harbin Medical University
Heilongjiang, China
- Jinan Central Hospital
Shandong, China
- Zhongshan Hospital Fudan University
Shanghai, China
- Xuzhou Central Hospital
Xuzhou, China
- First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
- Orszagos Onkologiai Intezet
Budapest, Hungary
- Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
Gyula, Hungary
- Bacs-Kiskun Megyei Oktatokorhaz
Kecskemét, Hungary
- Szszb Megyei Korhazak Es Egyetemi Oktatokorhaz
Nyíregyháza, Hungary
- Asl Regionale Piemonte - Ospedale Santo Spirito Casale Monferrato (ospedale Di Casale Monferrato)
Casale Monferrato, Alessandria, Italy
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Rome, Roma, Italy
- Fondazione Policlinico Universitario Agostino Gemelli Irccs
Rome, Roma, Italy
- Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
Cremona, Italy
- Azienda Ospedaliera Universitaria Careggi
Florence, Italy
- Szpitale Pomorskie Spółka Z Ograniczoną Odpowiedzialnością
Gdynia, Poland
- Szpital Specjalistyczny Im. L.Rydygiera W Krakowie
Krakow, Poland
- Mrukmed Lekarz Beata Madej Mruk I Partner Spółka Partnerska Oddział Nr 1 W Rzeszowie
Rzeszów, Poland
- Centrum Medyczne Pratia Poznan
Skórzewo, Poland
- Centrum Zdrowia Mdm
Warsaw, Poland
- Hospital Clinic de Barcelona
Barcelona, Spain
- Hospital Universitari Vall D'Hebron
Barcelona, Spain
- Ico L'Hospitalet - Hospital Duran I Reynals
Barcelona, Spain
- Hospital Universitari Arnau de Vilanova
Lleida, Spain
- Hospital Universitario Lucus Augsti
Lugo, Spain
- Hospital General Universitario Gregorio Marañon
Madrid, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Hospital Universitario Hm Madrid Sanchinarro
Madrid, Spain
- Hospital Universitario la Paz
Madrid, Spain
- Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- Hospital Universitario Virgen Macarena
Seville, Spain
- Hospital Universitario Virgen del Rocio
Seville, Spain
- Hospital Clinico Universitario de Valencia
Valencia, Spain
- Hospital Universitario Miguel Servet
Zaragoza, Spain
- Ci Cherkasy Regional Oncological Dispensary of Crc
Cherkasy, Ukraine
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Jan 2021
- Primary completion
- 13 Feb 2023
- Completion
- 31 Mar 2023
- Last update posted
- 26 Nov 2024
- Registered enrollment
- 326
- Registry id
- NCT04607668
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.